Wegovy Pill vs Injection: Key Differences, Effectiveness and Safety

Wegovy pill vs injection is a question many people considering semaglutide treatment are asking, particularly now that an oral formulation is available alongside the established weekly injection. Both contain semaglutide, a GLP-1 receptor agonist, and both are licensed in the UK for weight management — but they differ significantly in how they are taken, absorbed, and dosed. Understanding these differences is essential before starting treatment or considering a switch. This article explains the key clinical distinctions, compares the evidence, and outlines which option may suit different individuals.

Wegovy Pill vs Injection: The Main Differences

The Wegovy pill is taken once daily with strict fasting requirements, while the injection is given once weekly without fasting; despite containing the same active ingredient, they are not interchangeable and their milligram doses cannot be directly compared.

The Wegovy pill and Wegovy injection contain the same active ingredient, semaglutide, and both are GLP-1 receptor agonist treatments used for weight management. However, they are not interchangeable versions of the same medicine. They are taken, absorbed and dosed differently, and UK prescribing information warns that the effect of switching between oral and injected semaglutide cannot easily be predicted.

The most obvious difference is frequency. The Wegovy pill is taken once every day, while Wegovy injections are given once a week. For someone who dislikes needles, the tablet offers a needle-free alternative. For someone who prefers not to think about treatment every morning, the weekly injection may feel simpler.

According to the UK Summary of Product Characteristics (SmPC), Wegovy tablets should be taken on an empty stomach after fasting for at least 8 hours. The tablet is swallowed whole with a small amount of water, up to 120 mL, followed by a wait of at least 30 minutes before eating, drinking or taking other oral medicines. Food and larger volumes of water can reduce absorption.

Wegovy injections do not have the same fasting requirement. They are injected under the skin of the abdomen, thigh or upper arm and can be used at any time of day, with or without meals.

The dose schedules differ too. The oral regimen begins at 1.5 mg once daily, then increases no faster than monthly through 4 mg, 9 mg and 25 mg, with 25 mg as the standard maintenance dose. The standard injection schedule begins at 0.25 mg once weekly and increases over 16 weeks through 0.5 mg, 1 mg and 1.7 mg to 2.4 mg once weekly. Current UK prescribing information also allows the injection dose, if needed, to be increased to 7.2 mg once weekly in adults with obesity after at least four weeks on 2.4 mg.

These milligram numbers should not be compared directly. A 25 mg tablet is not automatically “stronger” than a 2.4 mg injection. Oral semaglutide has low and variable absorption, while an injection delivers the medicine by a different route. The UK SmPC notes broadly comparable average steady-state semaglutide concentrations with the 25 mg tablet and 2.4 mg injection, but more variability with oral treatment.

Is the Wegovy Pill as Effective as the Injection for Weight Loss?

Both formulations produce clinically meaningful average weight loss in trials, but no direct head-to-head study exists, so neither can be definitively called more effective than the other.

Both forms of Wegovy have produced substantial average weight loss in clinical trials, but the evidence needs careful interpretation. There has not been a direct head-to-head trial establishing that the Wegovy pill is better, worse or identical to the injection for weight loss. Comparing headline percentages from separate studies can therefore be misleading.

For the 25 mg Wegovy tablet, the current UK SmPC reports OASIS 4, a 64-week randomised placebo-controlled trial in adults with overweight or obesity. Under the trial's primary treatment-policy analysis, the estimated average change in body weight was -13.6% with oral semaglutide 25 mg compared with -2.2% with placebo. In an analysis estimating what would happen if all randomised participants remained on treatment and did not use additional anti-obesity therapies, the estimates were -16.6% and -2.8%.

For the 2.4 mg once-weekly injection, the UK SmPC reports STEP 1, a 68-week randomised placebo-controlled trial. The estimated average change in body weight was -14.9% with semaglutide 2.4 mg compared with -2.4% with placebo. Under an analysis assuming participants remained on treatment and did not use additional anti-obesity therapy or bariatric surgery, the estimates were -16.9% and -2.4%.

Those figures may look similar, but OASIS 4 and STEP 1 were separate studies involving different participants, durations and trial conditions. It would be incorrect to say that 16.6% for the pill “beats” 14.9% for the injection, or that 16.9% for the injection proves it is better. The figures are not a direct comparison.

The injection evidence base is older and broader, while the 25 mg oral formulation is newer. Current UK injection prescribing information also includes a 7.2 mg once-weekly option for some adults with obesity where needed. Results from that higher-dose injection programme still cannot be directly compared with the oral trial.

The most accurate conclusion is that both oral and injected Wegovy are evidence-based semaglutide treatments capable of producing clinically meaningful weight loss, but individual results vary. Treatment success also depends on adherence. A daily tablet may be a poor fit for someone who cannot follow the fasting instructions, while a weekly injection may be difficult for someone with severe needle anxiety.

Patients should therefore be cautious about claims that one version is categorically “more powerful”. The best option is the one that is clinically appropriate and can be used consistently.

Side Effects and Safety: Does the Pill Differ From the Injection?

Both forms share the same semaglutide side effect profile — most commonly gastrointestinal symptoms — though the pill carries additional absorption-related risks if fasting instructions are not followed correctly.

Because the Wegovy pill and injection both contain semaglutide, they share many of the same side effects and safety considerations. Changing from a needle to a tablet does not remove the pharmacological effects of semaglutide.

The most common problems are gastrointestinal. The MHRA lists nausea, diarrhoea, constipation and vomiting among the most common side effects of the Wegovy tablet, and similar effects are well recognised with injected semaglutide.^[3][1] Symptoms often occur during dose escalation, which is why both formulations start low and increase gradually.

For the pill, the schedule is at least one month at 1.5 mg, 4 mg and 9 mg before reaching 25 mg. For the standard injection regimen, the dose rises over 16 weeks from 0.25 mg to 0.5 mg, 1 mg, 1.7 mg and then 2.4 mg weekly. The injection SmPC advises that significant gastrointestinal symptoms may justify delaying escalation or lowering to the previous dose until symptoms improve. The oral SmPC similarly permits remaining at the previous dose level if needed.

Vomiting and diarrhoea can lead to dehydration, particularly in people with kidney problems. Severe or persistent abdominal symptoms should not simply be assumed to be normal. Semaglutide product information also includes warnings or precautions relating to acute pancreatitis, gallbladder disease and diabetic retinopathy complications in relevant patients.^[6][2]

Semaglutide should not be used during pregnancy. UK product information advises stopping it at least two months before a planned pregnancy because of its long half-life.^[1][2]

There are formulation-specific differences too. The pill must be swallowed whole and should not be split, crushed or chewed. The oral SmPC says it should be used as one tablet per day only; lower-strength tablets should not be combined to imitate a higher dose. If a tablet dose is missed, it should be skipped and the next dose taken the following day.

The injection avoids the fasting and absorption issue but requires correct injection technique and safe handling of the device.

The UK oral SmPC estimates the absolute bioavailability of oral semaglutide at around 1–2% and states that absorption is reduced by food or large volumes of water.^[1][7] It also records higher pharmacokinetic variability than with injected semaglutide. This is why patients should not improvise with timing or attempt direct milligram conversions between formulations.

Neither form should be combined with another GLP-1 receptor agonist without appropriate prescribing guidance.

Which Is Better for You: the Wegovy Pill or Injection?

The best formulation depends on individual clinical suitability, lifestyle, and ability to follow dosing instructions — the pill suits those who prefer needle-free treatment, while the injection suits those who find daily fasting impractical.

There is no single answer to whether the Wegovy pill or injection is better. Both contain semaglutide, but their practical demands are different enough that one may fit a person's routine and clinical circumstances better.

The Wegovy pill may be appealing to someone who:

• has significant anxiety about needles

• prefers taking medicine by mouth

• can reliably follow an overnight fast and 30-minute post-dose waiting period

• can separate Wegovy from other morning oral medicines as required

The Wegovy injection may be appealing to someone who:

• prefers once-weekly rather than once-daily treatment

• finds an 8-hour fast and strict timing difficult

• takes multiple oral medicines in the morning

• is comfortable using an injection pen

Preference is only one part of the decision. A prescriber will also consider BMI eligibility, weight-related health conditions, previous treatment, side effects, other medicines and medical history. Neither formulation is suitable for everyone.

The pill is needle-free, but it is not necessarily more convenient. Someone who eats immediately on waking, drinks coffee first thing or takes essential morning medicines may find the administration rules restrictive. The injection is more flexible around meals and only needs weekly dosing, but some people experience significant needle anxiety or difficulty handling injection devices.

People already taking Wegovy injections should not switch themselves based on milligram strengths. The UK SmPC says the effect of switching between oral and injected semaglutide cannot easily be predicted because oral absorption is more variable. It does provide one defined transition: a patient treated with semaglutide injection 2.4 mg once weekly can be transitioned to semaglutide tablets 25 mg once daily, starting the tablets one week after the last injection. This should still occur as part of a prescribed treatment plan.

That rule should not be generalised to every dose. Someone using 0.25 mg, 0.5 mg, 1 mg or 1.7 mg injections should not assume a tablet equivalent. Likewise, the 25 mg tablet should not be converted back to an injection by comparing packaging numbers. There is no simple milligram-for-milligram calculation.

In summary, the Wegovy pill offers a once-daily, needle-free way to take semaglutide, while the injection offers once-weekly dosing without fasting requirements. Clinical trials show meaningful average weight loss with both, but there is no direct head-to-head evidence proving one is universally more effective. The choice should be based on clinical suitability, the ability to follow dosing instructions, tolerability and a realistic treatment routine.

Anyone considering Wegovy should complete a clinical assessment and use the exact formulation and dose prescribed. Patients already using semaglutide or another GLP-1 medicine should speak to a prescriber before switching, stopping or combining treatments.

Scientific References

1. Wegovy 25 mg tablets – Summary of Product Characteristics (SmPC).
2. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
3. First GLP-1 tablet for weight loss approved in the UK.
4. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
5. Semaglutide – BNF / NICE.
6. Wegovy EPAR – Product Information.
7. Wegovy EPAR – Public Assessment Report.
8. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
9. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) – Wilding et al..
10. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) – Aronne et al..
11. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) – PubMed abstract.
12. Wegovy 2.4 mg FlexTouch – Package Leaflet: Information for the Patient.

Frequently Asked Questions